LLMS Central - The Robots.txt for AI

rheum-live.com

Last updated: 9/10/2026valid

Independent Directory - Important Information

This llms.txt file was publicly accessible and retrieved from rheum-live.com. LLMS Central does not claim ownership of this content and hosts it for informational purposes only to help AI systems discover and respect website policies.

This listing is not an endorsement by rheum-live.com and they have not sponsored this page. We are an independent directory service with no affiliation to the listed domain.

Copyright & Terms: Users should respect the original terms of service of rheum-live.com. If you believe there is a copyright or terms of service violation, please contact us at support@llmscentral.com for prompt removal. Domain owners can also claim their listing.

Current llms.txt Content

# Rheumatology Live

> Rheumatology Live - Healthcare Publication

- Base URL: https://www.rheum-live.com
- Generated: 2026-09-10T03:00:56.788Z
- Content updates: multiple times daily

## Content Access for AI Agents

This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML.

**Supported content types:**
- `text/markdown` — Clean Markdown with YAML frontmatter
- `text/plain` — Plain text (same as Markdown)
- `text/html` — Default HTML response

**Example request:**
```
curl -H "Accept: text/markdown" https://www.rheum-live.com/view/article-slug
```

**YAML frontmatter schema** (returned with every Markdown response):

| Field | Type | Description |
|-------|------|-------------|
| `title` | string | Article headline |
| `description` | string | Summary/excerpt (max 300 chars) |
| `url` | string | Canonical article URL |
| `canonical_url` | string | Canonical URL if different from `url` |
| `published` | ISO 8601 | Original publication date |
| `modified` | ISO 8601 | Last modification date |
| `authors` | string[] | Author display names |
| `content_type` | string | Content category (e.g., "News", "Clinical") |
| `categories` | string[] | Taxonomy categories |
| `tags` | string[] | SEO tags |
| `image` | string | Featured image URL |
| `publisher` | string | Publication/site name |

**Discovery headers** (included on all responses):
- `Link: <https://www.rheum-live.com/llms.txt>; rel="llms"` — RFC 8288 link to this file
- `X-Llms-Txt: https://www.rheum-live.com/llms.txt` — Explicit discovery header

## Usage Policy

- Robots policy: [https://www.rheum-live.com/robots.txt](https://www.rheum-live.com/robots.txt)
- Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329)
- Rate guidance: prefer RSS and sitemap feeds over crawling individual pages
- Attribution: All content © MJH Life Sciences. Include source URLs when citing.

## Content Categories

- [Clinical](https://www.rheum-live.com/clinical)
- [Conference](https://www.rheum-live.com/conference)
- [News](https://www.rheum-live.com/news)
- [Peer Exchange](https://www.rheum-live.com/peer-exchange)
- [Peers Perspectives](https://www.rheum-live.com/peers-perspectives)
- [Physician's Money Digest](https://www.rheum-live.com/physicians-money-digest)
- [Podcasts](https://www.rheum-live.com/podcasts)
- [Rheumatology](https://www.rheum-live.com/clinical)
- [Strategic Alliance Partnership](https://www.rheum-live.com/sap-partner)
- [Video Series](https://www.rheum-live.com/video-series)
- [Videos](https://www.rheum-live.com/videos)

## Featured Content

- [FDA Granted Certolizumab Pegol Breakthrough Status for APS in Pregnancy](https://www.rheum-live.com/view/certolizumab-pegol-fda-breakthrough-therapy-aps-pregnancy): The designation follows phase 2 IMPACT trial data showing reduced adverse pregnancy outcomes in high-risk antiphospholipid syndrome.
- [High BMI Lowers Odds of Achieving MDA in PsA on TNFi](https://www.rheum-live.com/view/high-bmi-lowers-odds-of-achieving-mda-in-psa-on-tnfi): In a large real-world PsA cohort, higher BMI reduced the odds of minimal disease activity, especially with TNF inhibitors other than infliximab.
- [5 Headlines You Missed in August 2026](https://www.rheum-live.com/view/5-pulmonology-headlines-you-missed-in-august-2026): August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
- [Joint Ventures: Unpacking the History and Modern Use of Steroids in Rheumatology](https://www.rheum-live.com/view/joint-ventures-unpacking-the-history-and-modern-use-of-steroids-in-rheumatology): Hosts Buss and Arnold trace glucocorticoids from their 1948 discovery to today's steroid-sparing dilemmas in RA and lupus.
- [Model Predicts Persistent Arthritis After Checkpoint Inhibitor Therapy](https://www.rheum-live.com/view/model-predicts-persistent-arthritis-checkpoint-inhibitor-therapy): Kate Harnden, MBChB, discusses new study that identifies factors tied to disease persistence in patients with immune checkpoint inhibitor-induced arth...
- [Ethnicity Drives Unequal Steroid Use in Lupus, With Sarah Dyball, PhD](https://www.rheum-live.com/view/ethnicity-drives-unequal-steroid-use-lupus-sarah-dyball-phd): Population data from Greater Manchester show Black, Asian, and mixed-ethnicity patients with lupus receive greater oral corticosteroid doses.
- [FDA Approves First Oral Treatment of Dermatomyositis in Adult Patients](https://www.rheum-live.com/view/fda-approves-first-oral-treatment-of-dermatomyositis-in-adult-patients): The approval adds brepocitinib (Lisraya), an oral JAK/TYK2 inhibitor, as the first agent specifically studied and approved for dermatomyositis in adul...
- [Trial Design Drives Radiographic Outcomes Across IL-23 Inhibitors in PsA](https://www.rheum-live.com/view/trial-design-radiographic-outcomes-across-il-23-inhibitors-psa): Baseline structural damage accounted for most of the variance in placebo-arm radiographic progression across 6 PsA trials.
- [FDA Approves Garetosmab-grts for Fibrodysplasia Ossificans Progressiva ](https://www.rheum-live.com/view/fda-approves-garetosmab-grts-for-fibrodysplasia-ossificans-progressiva): Garetosmab-grts is the first treatment demonstrating reduced new heterotopic ossification lesions and flare-ups in adults with FOP.
- [ALKIVIA: Efgartigimod Improves Myositis, Hits Phase 3 Primary End Point](https://www.rheum-live.com/view/alkivia-efgartigimod-improves-myositis-hits-phase-3-primary-end-point): Efgartigimod produced significant, sustained improvement in autoimmune myositis, including the first positive phase 3 results in IMNM.

## Feeds and Indexes

- [RSS Feed](https://www.rheum-live.com/rss.xml): Latest articles in XML syndication format
- [Sitemap](https://www.rheum-live.com/sitemap.xml): Complete URL index for all published pages
- [News Sitemap](https://www.rheum-live.com/sitemap-news.xml): Recent articles optimized for news indexing
- [Authors Directory](https://www.rheum-live.com/authors): Browse all contributors and their published work

Version History

Version 19/10/2026, 3:02:35 AMvalid
6202 bytes

Categories

newshealth

Visit Website

Explore the original website and see their AI training policy in action.

Visit rheum-live.com

Content Types

articlespages

Recent Access

No recent access

API Access

Canonical URL:
https://llmscentral.com/rheum-live.com/llms.txt
API Endpoint:
/api/llms?domain=rheum-live.com
rheum-live.com - llms.txt File | AI Training Guidelines | LLMS Central